CIK 0000887359 · Large accelerated filer
Vericel Corp
Sign in to watch- Ticker
- VCEL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- MI
- Entity type
- operating
- EIN
- 943096597
- Phone
- 6175885555
- Business address
- 25 BLUE SKY DRIVE, BURLINGTON, MA, 01803
- Former names
- AASTROM BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,787,802
- in 7 filings, $5.8M under 10b5-1 plans
Net −$5,787,802. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Mara Joseph Anthony Jr −$4.1M Chief Financial Officer sold 82% of stake
- Flynn Sean C. −$779K Chief Legal Officer sold 88% of stake
- MCLAUGHLIN KEVIN F −$413K Director sold 28% of stake
- ZERBE ROBERT L MD −$386K Director sold 19% of stake
- SIEGAL JONATHAN −$79K Principal Accounting Officer sold 54% of stake
Reading 65 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2013-05-02 | Rubino Alan L Director | Grant or award · Stock option (right to buy) | +60,000 | $0.53 | $32K | 60,000 |
| 2013-05-02 | SIMS NELSON M Director | Grant or award · Stock option (right to buy) | +60,000 | $0.53 | $32K | 60,000 |
| 2013-05-02 | ZERBE ROBERT L MD Director | Grant or award · Stock option (right to buy) | +60,000 | $0.53 | $32K | 60,000 |
| 2012-10-23 | CRESSWELL RONALD M Director | Grant or award · Stock Option (right to buy) | +60,000 | $1.47 | $88K | 60,000 |
| 2012-10-23 | Rubino Alan L Director | Grant or award · Stock Option (right to buy) | +60,000 | $1.47 | $88K | 60,000 |
| 2012-10-23 | SIMS NELSON M Director | Grant or award · Stock Option (right to buy) | +60,000 | $1.47 | $88K | 60,000 |
| 2012-10-23 | Urschel Harold C Jr Director | Grant or award · Stock Option (right to buy) | +60,000 | $1.47 | $88K | 60,000 |
| 2012-10-23 | ZERBE ROBERT L MD Director | Grant or award · Stock Option (right to buy) | +60,000 | $1.47 | $88K | 60,000 |
| 2012-08-29 | MAYLEBEN TIMOTHY M President and CEO | Returned to the company · Stock Option (right to buy) | +317,000 | $1.49 | $472K | 78,000 |
| 2012-08-29 | MAYLEBEN TIMOTHY M President and CEO | Grant or award · Stock Option (right to buy) | +283,000 | $1.67 | $473K | 283,000 |
| 2012-06-25 | MAYLEBEN TIMOTHY M President and CEO | Returned to the company · Stock Option (right to buy) | +481,164 | $2.26 | $1.1M | 218,711 |
| 2012-06-25 | MAYLEBEN TIMOTHY M President and CEO | Grant or award · Stock Option (right to buy) | +481,164 | $2.26 | $1.1M | 481,164 |
| 2012-06-25 | Bartel Ronnda Chief Scientific Officer | Returned to the company · Stock Option (right to buy) | +107,594 | $2.26 | $243K | 48,906 |
| 2012-06-25 | Bartel Ronnda Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +107,594 | $2.26 | $243K | 107,594 |
| 2012-06-25 | Watling Sharon VP Clinical Development | Returned to the company · Stock Option (right to buy) | +151,937 | $2.26 | $343K | 69,063 |
| 2012-06-25 | Watling Sharon VP Clinical Development | Grant or award · Stock Option (right to buy) | +151,937 | $2.26 | $343K | 151,937 |
| 2012-05-03 | Gibson Brian Vice President | Grant or award · Stock Option (right to buy) | +195,000 | $2.49 | $486K | 195,000 |
| 2012-05-03 | Bartel Ronnda Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +124,500 | $2.49 | $310K | 124,500 |
| 2012-05-03 | Gibson Brian Vice President | Grant or award · Stock Option (right to buy) | +305,000 | $2.49 | $759K | 305,000 |
| 2012-05-03 | Watling Sharon VP Clinical Development | Grant or award · Stock Option (right to buy) | +117,000 | $2.49 | $291K | 117,000 |
Page 69 of 75 · 1,497 trades